Análise de citocinas e CD68 na aorta: novos parâmetros para estudo da inflamação no diabete melito tipo 2
Barra lateral de artigos
Conteúdo do artigo principal
Resumo
Introdução: A patogênese das doenças cardiovasculares contemporâneas tem, na aterosclerose representação central. Elas podem ser definida como processo inflamatório de progressão lenta e associado a vários fatores causais. O processo fisiopatológico é caracterizado por complexa cascata inflamatória, iniciada por lesão do endotélio vascular, levando ao estreitamento e endurecimento vascular.
Objetivo: Revisar a presença de processo inflamatório sistêmico através da análise dos marcadores interleucina-6 e fator de necrose tumoral alfa (TNF-a) na manifestação inflamatória tecidual em diferentes segmentos da artéria aorta.
Método: Revisão integrativa realizada nas bases de dados PubMed e Scielo. A busca utilizou as seguintes palavras-chave: “inflamação. aterosclerose. diabete melito tipo 2, CD68, IL-6,THFa, endotélio” e suas versões ao inglês Os critérios de inclusão compreenderam artigos de revisão, estudos experimentais, pesquisas pré-clínicas e clínicas, escritos em português e inglês e disponíveis em texto completo. Os artigos selecionados foram analisados com base nas tecnologias abordadas, perspectivas futuras e desafios mencionados, doenças referidas relacionados à ideia central do artigo.
Resultado: Foram avaliados 63 artigos.
Conclusão: As citocinas pró-inflamatórias, são exemplos de marcadores inflamatórios com expressão sorológica. Marcadores inflamatórios teciduais, como por exemplo o CD68, glicoproteína de ativação de macrófagos, identificada através de estudo imuno-histoquímico, podem permitir a avaliação do processo inflamatório vascular, especialmente no contexto da aterosclerose.
Detalhes do artigo
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Referências
Zhang Y. Editorial: Ideal cardiovascular health and sudden cardiac death. Rev Eur Cardiol Prev. 2021;28(3):293. https://doi.org/10.1177/2047487320913710
Libby P, Ridker PM, Maseri A. Inflammation and Atherosclerosis. Circulation. 2002;105(9):1430-52. https://doi.org/10.1161/hc0902.104353
Chistiakov DA, Orekhov AN, Bobryshev YV. Effects of shear stress on endothelial cells: go with the flow. Acta Physiol. 2017;219(2):335-6. https://doi.org/10.1111/apha.12725
Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045-51. https://doi.org/10.1161/ATVBAHA.108.179705
Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes Mellitus and Inflammation. Curr Diab Rep. 2013;13(3):435-44. https://doi.org/10.1007/s11892-013-0375-y
Rani V, Deep G, Singh RK, Palle K, Yadav UCS. Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Life Sci. 2016;148:183-93. https://doi.org/10.1016/j.lfs.2016.02.002
Brito-Casillas Y, Melián C, Wägner AM. Study of the pathogenesis and treatment of diabetes mellitus through animal models. Endocrinol Nutr. 2016;63(7):345-53. https://doi.org/10.1016/j.endonu.2016.03.011
Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circ Res. 2019;124(2):315-27. https://doi.org/10.1161/CIRCRESAHA.118.313591
Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204-12. https://doi.org/10.1038/ni.2001
Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045-51. https://doi.org/10.1161/ATVBAHA.108.179705
Boarescu PM, Boarescu I, Pop RM, Roşian ŞH, Bocșan IC, Rus V, et alEvaluation of Oxidative Stress Biomarkers, Pro-Inflammatory Cytokines, and Histological Changes in Experimental Hypertension, Dyslipidemia, and Type 1 Diabetes Mellitus. Int J Mol Sci. 2022;23(3):1438. https://doi.org/10.3390/ijms23031438
Barkas F, Sener YZ, Golforoush PA, Kheirkhah A, Rodriguez-Sanchez E, Novak J, et al. Advancements in risk stratification and management strategies in primary cardiovascular prevention. Atherosclerosis. 2024;395:117579. https://doi.org/10.1016/j.atherosclerosis.2024.117579
Estudo Framingham (Framingham Heart Study). Available from: https://www.nhlbi.nih.gov/science/framingham-heart-study-fhs
Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11:117. https://doi.org/10.1186/1741-7015-11-117
Niiranen TJ, Lyass A, Larson MG, Hamburg NM, Benjamin EJ, Mitchell GF, et al. Prevalence, correlates, and prognosis of healthy vascular aging in a western community-dwelling cohort: The Framingham Heart Study. Hypertension. 2017;70(2):267-74. https://doi.org/10.1161/HYPERTENSIONAHA.117.09026
Andersson C, Nayor M, Tsao CW, Levy D, Vasan RS. Framingham Heart Study: JACC Focus Seminar, 1/8. J Am Coll Cardiol. 2021;77(21):2680-92. https://doi.org/10.1016/j.jacc.2021.01.059
de Oliveira GMM, Brant LCC, Polanczyk CA, Malta DC, Biolo A, Nascimento BR, et al. Estatísticas Cardiovasculares – Brasil 2023. Arq. Soc. Cardiol. 2024;121(2):e20240079. https://doi.org/10.36660/abc.20240079
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics - 2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-e621. https://doi.org/10.1161/cir.0000000000001123
Plano Estratégico OMS (Organização Mundial da Saúde) / OPAS (Organização Pan-Americana da Saúde) 2014-2019 – COPAS- Tecnologia de Equipamentos e Provisões; Doenças Cardiovasculares; Atenção Primária à Saúde; Estilo de Vida Saudável. Available from: https://gov.br/iris.paho.org/handle/10665.2/51769
Feigin VL, Owolabi MO. Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission. Lancet Neurol. 2023;22(12):1160-206. https://doi.org/10.1016/S1474-4422(23)00277-6
Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Sommer M, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. https://doi.org/10.1038/s41572-019-0106-z
Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11:117. https://doi.org/10.1186/1741-7015-11-117
Libby P. Inflammation and the pathogenesis of atherosclerosis. Vascul Pharmacol. 2024;154:107255. https://doi.org/10.1016/j.vph.2023.107255
Gimbrone MA Jr, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016;118(4):620-36. https://doi.org/10.1161/CIRCRESAHA.115.306301
Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet. 2017;18(6):331-44. https://doi.org/10.1038/nrg.2016.160
Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118(4):692-702. https://doi.org/10.1161/circresaha.115.306361
Bäck M, Yurdagul A Jr, Tabas I, Öörni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16(7):389-406. https://doi.org/10.1038/s41569-019-0169-2
Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678-89. https://doi.org/10.1038/nri2156
Ley K. Inflammation and atherosclerosis. Cells. 2021;10(5):1197. https://doi.org/10.3390/cells10051197
Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709-21. https://doi.org/10.1038/nri3520
Tabas I, Lichtman AH. Monocyte-macrophages and T cells in atherosclerosis. Immunity. 2017;47(4):621-34. https://doi.org/10.1016/j.immuni.2017.09.008
Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):1852-66. https://doi.org/10.1161/circresaha.114.302721
Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis. Circ Res. 2016;118(4):653-67. https://doi.org/10.1161/circresaha.115.306256
Ylä-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, et al. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. Thromb Haemost. 2011;106(1):1-19. https://doi.org/10.1160/th10-12-0784
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-95. https://doi.org/10.1056/nejmra043430
Rothwell PM. Atherothrombosis and ischaemic stroke. BMJ. 2007;334(7590):379-80. https://doi.org/10.1136/bmj.38964.489051.80
Sacco RL. Evolution from stroke risk factors to brain health determinants. Cerebrovasc Dis. 2015;40(3-4):102-13. https://doi.org/10.1159/000437285
Creager MA. Protecting life and limb in peripheral artery disease. Circulation. 2018;137(4):351-53. https://doi.org/10.1161/circulationaha.117.032422
Baman JR, Eskandari MK. What is an abdominal aortic aneurysm? JAMA. 2022;328(22):2280. https://doi.org/10.1001/jama.2022.18638
Jalalzadeh H, Indrakusuma R, Planken RN, Legemate DA, Koelemay MJW, Balm R. Inflammation as a predictor of abdominal aortic aneurysm growth and rupture: A systematic review of imaging biomarkers. Eur J Vasc Endovasc Surg. 2016;52(3):333-42. https://doi.org/10.1016/j.ejvs.2016.05.002
Virani SS, Alonso A, Aparicio HJ, Bejamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics-2021 update: A report from the American Heart Association. Circulation. 2021;143(8):e254-e743. https://doi.org/10.1161/cir.0000000000000950
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. https://doi.org/10.1093/eurheartj/ehab484
Chen J, Yang Y, Kong W. Cross Talk between Inflammation and Metabolic Disorders. Mediators Inflamm. 2022;2022:9821506. https://doi.org/10.1155/2022/9821506
Li Z, Cong X, Kong W. Matricellular proteins: Potential biomarkers and mechanistic factors in aortic aneurysms. J Mol Cell Cardiol. 2022;169:41-56. https://doi.org/10.1016/j.yjmcc.2022.05.001
Yamamoto K, Saito Y, Hashimoto O, Nakayama T, Okino S, Sakai Y, et al. Biomarkers for Risk Stratification in Patients With Type A Acute Aortic Dissection. Am J Cardiol. 2024;212:103-8. https://doi.org/10.1016/j.amjcard.2023.11.053
Puertas-Umbert L, Almendra-Pegueros R, Jiménez-Altayó F, Sirvent M, Galán M, Martínez-González J, et al. Novel pharmacological approaches in abdominal aortic aneurysm. Clin Sci (Lond). 2023;137(15):1167-94. https://doi.org/10.1042/cs20220795
Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci. 2019;20(9):2358. https://doi.org/10.3390/ijms20092358
49. Luna P, Guarner V, Farías JM, Hernández-Pacheco G, Martínez M. Importance of Metabolic Memory in the Development of Vascular Complications in Diabetic Patients. J Cardiothorac Vasc Anesth. 2016;30(5):1369-78. https://doi.org/10.1053/j.jvca.2016.02.008
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107. https://doi.org/10.1038/nri2925
Reilly SM, Saltiel AR. Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 2017;13(11):633-43. https://doi.org/10.1038/nrendo.2017.90
Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141-50. https://doi.org/10.1016/j.diabres.2014.04.006
Sharma BR, Kanneganti TD. NLRP3 inflammasome in cancer and metabolic diseases. Nat Immunol. 2021;22(5):550-9. https://doi.org/10.1038/s41590-021-00886-5
Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2020;20(1):40-54. https://doi.org/10.1038/s41577-019-0198-4
Zhou Z, Sun B, Yu D, Zhu C. Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus. Front Cell Infect Microbiol. 2022;12:834485. https://doi.org/10.3389/fcimb.2022.834485
Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001;50(6):537–46.
Ghasemi A, Khalifi S, Jedi S. Streptozotocin-nicotinamide-induced rat model of type 2 diabetes (review). Acta Physiologica Hungarica. 2014;101(4):408–20. https://doi.org/10.1556/APhysiol.101.2014.4.2
Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005;52(4):313–20. https://doi.org/10.1016/j.phrs.2005.05.004
Satrom KM, Ennis K, Sweis BM, Matveeva TM, Chen J, Hanson L, et al. Neonatal hyperglycemia induces CXCL10/CXCR3 signaling and microglial activation and impairs long-term synaptogenesis in the hippocampus and alters behavior in rats. 2018;15(1):82. https://doi.org/10.1186/s12974-018-1121-9
Carvalhal SRS. Efeito da suplementação com óleo de peixe rico em AGPI sobre parâmetros metabólicos e cognitivos em modelo experimental de diabetes mellitus tipo 2 [tese de doutorado]. Universidade Federal do Paraná; 2022. Available from: https://hdl.handle.net/1884/89201.
Wang Y, Gao P, Li F, Du J. Insights on aortic aneurysm and dissection: Role of the extracellular environment in vascular homeostasis. J Mol Cell Cardiol. 2022;171:90-101. https://doi.org/10.1016/j.yjmcc.2022.06.010
Coons AH. Immunofluorescence. Public Health Rep (1896). 1960;75(10):937-43.
Bittencourt JC, Elias CF. Métodos em Neurociência. 1ª ed. São Paulo: Editora Roca Ltda; 2007.
Sattler S, Kennedy-Lydon T. The Immunology of Cardiovascular Homeostasis and Pathology. 1st ed. Switzerland: Springer; 2017.